MedTrace Logo

A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®

NCT01820728 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2021-04-15

No results posted yet for this study

Summary

open label, active-controlled, randomized, parallel group, comparative study.

Conditions

Interventions

DRUG

DA-3801 Injection

DRUG

Gonal-F®

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Eung Gi Min, M.D., Ph.D. · Dongguk University Hospital

  • Chang Suk Suh, M.D., Ph.D. · Seoul National University Bundang Hospital

  • Doo Seok Choi, M.D., Ph.D. · Samsung Medical Center

  • Chung Hoon Kim, M.D., Ph.D. · Asan Medical Center

  • Jong Min Park, M.D.,Ph.D. · Gachon University Gil Medical Center

  • Kyung Joo Hwang, M.D., Ph.D. · Ajou University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01820728 on ClinicalTrials.gov